Beone Medicines Ltd.(688235),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

688235 Beone Medicines Ltd.

Closed 12-19 15:00:01

274.00

+2.34

+0.86%

High274.88	Low269.79	Vol1.80M
Open272.00	D1 Closing271.66	Amplitude1.87%
Mkt Cap422.23B	Tradable Cap31.51B	Total Shares1.54B
T/O490.00M	T/O Rate1.56%	Tradable Shares115.00M
P/B14.39	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"688235","market":"SH","secType":"STK","nameCN":"Beone Medicines Ltd.","latestPrice":274,"timestamp":1766127601000,"preClose":271.66,"halted":0,"volume":1799606,"delay":0,"changeRate":0.0086,"floatShares":114999999,"shares":1541000000,"eps":-0.0994,"marketStatus":"Closed","change":2.34,"latestTime":"12-19 15:00:01","open":272,"high":274.88,"low":269.79,"amount":490000000,"amplitude":0.0187,"askPrice":274,"askSize":34,"bidPrice":273.97,"bidSize":2,"shortable":0,"etf":0,"ttmEps":-0.0994,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1766367000000},"marketStatusCode":5,"adr":0,"adjPreClose":271.66,"symbolType":"stock_kcb","openAndCloseTimeList":[[1766107800000,1766115000000],[1766120400000,1766127600000]],"highLimit":298.83,"lowLimit":244.49,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1540677809,"isCdr":false,"pbRate":14.39,"roa":"--","roe":"4.26%","epsLYR":-3.64,"committee":-0.779817,"marketValue":422146000000,"turnoverRate":0.0156,"status":0,"afterMarket":{"amount":0,"volume":0,"close":274,"buyVolume":0,"sellVolume":0,"time":1766129639585,"indexStatus":"Closed 12-19 15:30:00","preClose":271.66},"hkstockBrief":{"symbol":"06160","market":"HK","secType":"STK","nameCN":"BEIGENE","latestPrice":185.1,"timestamp":1766131686007,"preClose":184.3,"halted":0,"volume":3354755,"delay":0,"premium":"-38.90"},"floatMarketCap":31525000000},"requestUrl":"/m/hq/s/688235/tweets","defaultTab":"tweets","newsList":[{"id":"2592216165","title":"BeOne Medicines Secures New Financing Facility with HSBC-Led Lenders","url":"https://stock-news.laohu8.com/highlight/detail?id=2592216165","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592216165?lang=en_us&edition=fundamental","pubTime":"2025-12-19 19:06","pubTimestamp":1766142375,"startTime":"0","endTime":"0","summary":"BeOne Medicines AG has entered into a new Facilities Agreement with a syndicate of financial institutions, including The Hongkong and Shanghai Banking Corporation Limited acting as global coordinator, lead arranger, and agent. Under this agreement, BeOne Medicines AG and certain subsidiaries secured new financing, enabling the company to fully repay and terminate its previous credit facility with China Merchants Bank Co., Ltd., originally dated December 9, 2024. All commitments, guarantees, and security interests related to the former facility were also terminated, with no penalties incurred in connection with the repayment and closure of the prior arrangement.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BeOne Medicines AG published","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251219:nNDL2Dx9BV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320764243.SGD","LU1781817850.SGD","SGXZ49509284.SGD","LU0456827905.SGD","LU2213484517.USD","LU2495084118.USD","600036","LU0029874905.USD","BK0188","LU1997245177.USD","BK0012","LU0708995153.HKD","LU2148510915.USD","LU2097828805.USD","BK0028","LU1969619763.USD","LU1064131003.USD","LU1146622755.USD","BK0010","LU0229945570.USD","BK0187","LU0140636845.USD","LU0821914370.USD","LU2097828474.EUR","LU1820825898.SGD","LU2580892789.USD","LU0047713382.USD","BK0070","LU1064130708.USD","LU1979443071.USD","LU2097828557.USD","LU1997244956.HKD","LU1655091616.SGD","LU2097828714.EUR","LU2289578879.USD","LU2328871848.SGD","LU0051755006.USD","SG9999000459.SGD","688235","BK0015","LU1048596156.SGD","LU0210526637.USD","SGXZ81163826.USD","LU1580142542.USD","LU1255011170.USD","LU0543330566.HKD","LU0011963245.USD","LU1934453819.USD","LU0128522744.USD","BK0278"],"gpt_icon":0},{"id":"2592597726","title":"BeOne Medicines AG Awards Dr. Lai Wang $10 Million Equity Grant and $750,000 Salary as President of R&D","url":"https://stock-news.laohu8.com/highlight/detail?id=2592597726","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592597726?lang=en_us&edition=fundamental","pubTime":"2025-12-18 19:08","pubTimestamp":1766056081,"startTime":"0","endTime":"0","summary":"BeOne Medicines Ltd. has announced updated compensation terms for Dr. Lai Wang, who has been appointed President, Global Head of Research and Development effective January 1, 2026. Dr. Wang will receive an annual salary of $750,000, with eligibility for an annual target bonus equal to 75% of his base salary, based on individual and corporate performance. Additionally, he will be granted a one-time equity incentive award of $10 million in restricted share units, vesting in four equal annual installments, with provisions for accelerated vesting under certain termination events.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BeOne Medicines AG published the original content used to generate this news brief via EDGAR, the Electronic Data G","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nNDL20kt5J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","688235"],"gpt_icon":0},{"id":"2592397718","title":"FDA Grants Fast Track Designation to BeOne Medicines' BGB-B2033 for Liver Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2592397718","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592397718?lang=en_us&edition=fundamental","pubTime":"2025-12-18 19:00","pubTimestamp":1766055629,"startTime":"0","endTime":"0","summary":"BeOne Medicines AG has received Fast Track Designation from the U.S. Food and Drug Administration  for its investigational treatment BGB-B2033, a GPC3x4-1BB bispecific antibody, for adult patients with hepatocellular carcinoma  who have experienced disease progression following prior systemic treatment. The designation is intended to expedite the development and review of therapies that address unmet medical needs in serious conditions. BeOne is currently conducting a global Phase 1 clinical trial to evaluate the safety and anti-tumor activity of BGB-B2033, both as a monotherapy and in combination with the PD-1 inhibitor TEVIMBRA .Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BeOne Medicines AG published the original content used to ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nNDL5RZth:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688235","BK0239"],"gpt_icon":0},{"id":"2592977919","title":"Beone Medicines Granted U.S. FDA Fast Track Designation for Bgb-B2033 as Treatment for Hepatocellular Carcinoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2592977919","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592977919?lang=en_us&edition=fundamental","pubTime":"2025-12-18 19:00","pubTimestamp":1766055601,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nTUABFB4DL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK0239","688235"],"gpt_icon":0},{"id":"1174588607","title":"Afternoon Plunge! HUABAO HANG SENG HONG KONG STOCK CONNECT INNOVATIVE DRUG SELECTION ETF (520880) Drops 2.77% to Hit New Low, Led by Heavyweights AKESO and BEIGENE","url":"https://stock-news.laohu8.com/highlight/detail?id=1174588607","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1174588607?lang=en_us&edition=fundamental","pubTime":"2025-12-15 13:40","pubTimestamp":1765777238,"startTime":"0","endTime":"0","summary":"On the afternoon of December 15, the Hong Kong Stock Connect innovative drug sector accelerated its decline, with the HUABAO HANG SENG HONG KONG STOCK CONNECT INNOVATIVE DRUG SELECTION ETF (520880)...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0561508036.HKD","LU1720050803.USD","LU1770034418.SGD","IE00B543WZ88.USD","LU0417516738.SGD","ONC","LU1251922891.USD","LU0588546209.SGD","LU0540923850.HKD","BK4526","LU1719994722.HKD","LU2476274720.SGD","LU2328871848.SGD","BK1574","IE00BPRC5H50.USD","LU0307460666.USD","BK4585","LU2399975544.HKD","LU0348767384.USD","BK4139","09926","LU0417516902.SGD","IE00B5MMRT66.SGD","LU2778985437.USD","BK1500","BK1588","06160","LU0348735423.USD","LU0348825331.USD","LU0348783233.USD","LU0634319403.HKD","LU2476274308.USD","688235","LU1794554557.SGD","LU1969619763.USD","LU1303224171.USD","LU2488822045.USD","BK1583","520880","LU0348766576.USD","BK1161","LU0348827113.USD","BK0239","LU0348784397.USD","LU0417516571.SGD","LU1961090484.USD"],"gpt_icon":0},{"id":"2589353552","title":"BeOne Medicines Reports 74% Six-Year Progression-Free Survival with BRUKINSA in Treatment-Naïve CLL","url":"https://stock-news.laohu8.com/highlight/detail?id=2589353552","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589353552?lang=en_us&edition=fundamental","pubTime":"2025-12-08 21:01","pubTimestamp":1765198892,"startTime":"0","endTime":"0","summary":"BeOne Medicines AG has announced new clinical data and future presentations related to its hematology portfolio, specifically focusing on BRUKINSA  and BGB-16673. At the 67th ASH Annual Meeting and Exposition in Orlando, Florida, the company highlighted long-term efficacy and safety data for BRUKINSA in treatment-nave chronic lymphocytic leukemia  and small lymphocytic lymphoma , demonstrating a 74% progression-free survival  rate at six years. Additionally, updated results from the ongoing Phase 1/2 CaDAnCe-101 study  evaluating BGB-16673 monotherapy in patients with B-cell malignancies were shared. These results showed an overall response rate  of 85.3% across all doses, with an ORR of 94.4% at the recommended phase 2 dose. The study also reported that 54.4% of patients remained on treatment at a median follow-up of 19.8 months. The 12- and 18-month PFS rates were 73.5% and 65.9%, respectively. BeOne Medicines AG stated that additional data from its CLL franchise will be presented at","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nNDL9C02Kt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688235","BK0239"],"gpt_icon":0},{"id":"2589809499","title":"BeOne Medicines AG Reports Promising Sonrotoclax Results in B-Cell Malignancies at ASH 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2589809499","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589809499?lang=en_us&edition=fundamental","pubTime":"2025-12-08 07:00","pubTimestamp":1765148420,"startTime":"0","endTime":"0","summary":"BeOne Medicines AG has announced new clinical data on sonrotoclax, a next-generation investigational BCL2 inhibitor, at the 67th American Society of Hematology  Annual Meeting & Exposition. The results demonstrate that sonrotoclax monotherapy achieved deep and durable clinical responses in patients with relapsed or refractory mantle cell lymphoma  and chronic lymphocytic leukemia . In combination with BRUKINSA, sonrotoclax showed rapid achievement of minimal residual disease  negativity in treatment-naive CLL, regardless of high-risk features. The overall response rate for sonrotoclax in R/R MCL was reported at 52.4%, and the best undetectable MRD rate in blood was 49.0%. Sonrotoclax monotherapy was generally well tolerated with manageable toxicities and no clinical tumor lysis syndrome observed. Updated data are scheduled to be presented on December 8, and the results are under review by China's National Medical Products Administration for potential accelerated approval.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251207:nNDL9G7LkX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688235","BK0239"],"gpt_icon":0},{"id":"1102399328","title":"BEIGENE (06160) Grants a Total of 21,300 Restricted Share Units","url":"https://stock-news.laohu8.com/highlight/detail?id=1102399328","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1102399328?lang=en_us&edition=fundamental","pubTime":"2025-12-04 17:00","pubTimestamp":1764838818,"startTime":"0","endTime":"0","summary":"BEIGENE (06160) announced that on November 28, 2025, the Board's Compensation Committee granted a total of 21,300 restricted share units (RSUs) in the form of American Depositary Shares (ADSs) to 147...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1770034418.SGD","ONC","LU1251922891.USD","LU0588546209.SGD","BK4526","LU1719994722.HKD","LU2328871848.SGD","LU0307460666.USD","BK4585","BK4139","BK1500","BK1588","06160","688235","LU1969619763.USD","LU1303224171.USD","BK1583","BK1161","BK0239"],"gpt_icon":0},{"id":"2586550402","title":"FDA Grants Priority Review to BeOne Medicines' Sonrotoclax for Relapsed or Refractory Mantle Cell Lymphoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2586550402","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586550402?lang=en_us&edition=fundamental","pubTime":"2025-11-26 19:00","pubTimestamp":1764154819,"startTime":"0","endTime":"0","summary":"The U.S. Food and Drug Administration  has accepted and granted Priority Review to the New Drug Application  submitted by BeOne Medicines AG for sonrotoclax, a next-generation BCL2 inhibitor, for the treatment of adult patients with relapsed or refractory (R/R) mantle cell lymphoma  following treatment with a Bruton's tyrosine kinase  inhibitor. The NDA is supported by positive data from a global Phase 1/2 study in this patient population. Sonrotoclax is also under regulatory review for R/R MCL and R/R chronic lymphocytic leukemia/small lymphocytic lymphoma  by the Center for Drug Evaluation  of the China National Medical Products Administration , with potential for accelerated approval. Additionally, BeOne intends to submit data to other global regulatory bodies, including participation in the FDA's Project Orbis initiative for concurrent international review.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251126:nNDL7Vj68q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","688235"],"gpt_icon":0},{"id":"2586256855","title":"U.S. FDA Grants Priority Review to Sonrotoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2586256855","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586256855?lang=en_us&edition=fundamental","pubTime":"2025-11-26 19:00","pubTimestamp":1764154801,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251126:nTUA8DDLYC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["688235","BK0239"],"gpt_icon":0},{"id":"2585645844","title":"Beone Medicines : Truist Securities Initiates Coverage With Buy Rating; Target Price $400","url":"https://stock-news.laohu8.com/highlight/detail?id=2585645844","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585645844?lang=en_us&edition=fundamental","pubTime":"2025-11-24 20:35","pubTimestamp":1763987717,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251124:nFWN3X00GS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK0239","BK4139","BK4585","688235","ONC","BK4526"],"gpt_icon":0},{"id":"2584380781","title":"BeOne Medicines Unveils Promising Clinical Data on Novel BCL2 and BTK Therapies at ASH 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2584380781","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584380781?lang=en_us&edition=fundamental","pubTime":"2025-11-20 19:00","pubTimestamp":1763636451,"startTime":"0","endTime":"0","summary":"BeOne Medicines AG has announced the presentation of new clinical data from its hematology portfolio at the upcoming 67th American Society of Hematology  Annual Meeting and Exposition, scheduled for December 6-9, 2025, in Orlando, Florida. Nearly 50 abstracts have been accepted, including six oral presentations. Key highlights include results from the Phase 1/1b study of the BCL2 inhibitor sonrotoclax in combination with obinutuzumab for treatment-nave CLL/SLL, as well as initial data on a triplet regimen of sonrotoclax, BRUKINSA , and obinutuzumab. Preliminary findings from a Phase 1/1b study of BGB-21447, a next-generation BCL2 inhibitor in patients with B-cell non-Hodgkin lymphoma, will also be shared. These results will be presented at the ASH 2025 meeting.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251120:nNDL9nrpyV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","688235"],"gpt_icon":0},{"id":"2584262339","title":"BeOne Medicines Q3 Net Profit At 688.8 Million Yuan","url":"https://stock-news.laohu8.com/highlight/detail?id=2584262339","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584262339?lang=en_us&edition=fundamental","pubTime":"2025-11-20 00:51","pubTimestamp":1763571099,"startTime":"0","endTime":"0","summary":"Nov 6 (Reuters) - BeOne Medicines AG <688235.SS>::*Q3 NET PROFIT 688.8 MILLION YUAN ($96.70 million)  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))  Source Date/Time = 06-NOV-202511:45:40 GMT","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nRSD2MkB6R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688235","BK0239"],"gpt_icon":0},{"id":"2584489689","title":"BRIEF-BeOne Medicines said Facilities Agreement provides U.S. Dollar-denominated, B1 revolving loan facility of $140 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2584489689","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584489689?lang=en_us&edition=fundamental","pubTime":"2025-11-19 19:18","pubTimestamp":1763551133,"startTime":"0","endTime":"0","summary":"BRIEF-BeOne Medicines said Facilities Agreement provides U.S. Dollar-denominated, B1 revolving loan facility of $140 millionNov 19  - BeOne Medicines AG 688235.SS:BEONE MEDICINES LTD - FACILITIES AGREEMENT PROVIDES U.S. DOLLAR-DENOMINATED, B1 REVOLVING LOAN FACILITY OF $140 MILLIONBEONE MEDICINES LTD - FACILITIES AGREEMENT PROVIDES U.S. DOLLAR-DENOMINATED, B2 TERM LOAN FACILITY OF $560 MILLIONBEONE MEDICINES LTD - FACILITIES AGREEMENT PROVIDES RENMINBI-DENOMINATED, A TERM LOAN FACILITY OF ABOUT $300 MILLIONBEONE MEDICINES LTD - ACCORDION FEATURE ALLOWS B LOAN FACILITIES INCREASE TO $700 MILLION - SEC FILINGFurther company coverage: 688235.SS ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nFWN3WV0QD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688235","BK0239"],"gpt_icon":0},{"id":"2584948676","title":"Beone Medicines Ltd - Accordion Feature Allows B Loan Facilities Increase to $700 Mln - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2584948676","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584948676?lang=en_us&edition=fundamental","pubTime":"2025-11-19 19:13","pubTimestamp":1763550792,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nFWN3WV0QD:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK0239","688235"],"gpt_icon":0},{"id":"2584894863","title":"Beone Medicines Ltd - Facilities Agreement Provides U.S. Dollar-Denominated, B1 Revolving Loan Facility of $140 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2584894863","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584894863?lang=en_us&edition=fundamental","pubTime":"2025-11-19 19:13","pubTimestamp":1763550792,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nFWN3WV0QD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["688235","BK0239"],"gpt_icon":0},{"id":"2584948866","title":"BeOne Medicines Secures $440 Million Dual-Currency Loan Facilities Led by HSBC","url":"https://stock-news.laohu8.com/highlight/detail?id=2584948866","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584948866?lang=en_us&edition=fundamental","pubTime":"2025-11-19 19:03","pubTimestamp":1763550231,"startTime":"0","endTime":"0","summary":"BeOne Medicines AG has entered into a new senior secured financing agreement with a group of financial institutions, including The Hongkong and Shanghai Banking Corporation Limited  as global coordinator. The Facilities Agreement, signed on November 13, 2025, provides BeOne Medicines with a U.S. dollar-denominated revolving loan facility of $140 million and a Renminbi-denominated term loan facility equivalent to approximately $300 million. The agreement includes financial covenants such as maintaining a minimum cash interest coverage ratio, net leverage ratio, and minimum consolidated shareholders' equity, among others. The initial drawdown is subject to customary regulatory approvals, and the agreement features an uncommitted accordion option that could increase total financing up to $700 million, although the company does not expect to exercise this option in the near term.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nNDL25FQ4W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0106831901.USD","LU0964806797.USD","LU0149721374.USD","LU0588546209.SGD","LU2449936058.SGD","LU0634319403.HKD","LU0164880469.USD","688235","BK0239","LU0898667661.SGD","LU0572940350.SGD","LU0348735423.USD","LU0831103253.SGD","LU2293690249.USD","LU0417516738.SGD","LU0264606111.USD","LU1481107354.HKD","LU0307460666.USD","LU0516422366.SGD","LU1003076772.USD","LU1023061713.HKD","LU1153584641.USD","LU2114397693.USD","LU2091194634.USD","BK5152","LU1015430645.USD","LU0171293334.USD","LU0516423091.SGD","LU0516423174.USD","LU0516422952.EUR","LU0171281750.USD","LU1019634622.SGD","IE0034235071.USD","LU0540923850.HKD","LU2539964713.USD","LU1019632923.USD","LU0572939691.SGD","LU1051770623.HKD","LU1668664300.SGD","LU0516422440.USD","LU2293690082.USD","HSBA.UK","LU1023061473.USD","LU0575583348.USD"],"gpt_icon":0},{"id":"1111797116","title":"BEIGENE Opens Over 3% Higher in Early Trading; CSCI Maintains \"Buy\" Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=1111797116","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1111797116?lang=en_us&edition=fundamental","pubTime":"2025-11-18 09:40","pubTimestamp":1763430018,"startTime":"0","endTime":"0","summary":"BEIGENE (06160) opened more than 3% higher in early trading. At the time of writing, the stock was up 3.53% to HK$223.2, with a turnover of HK$11.96 million. On November 17, BEIGENE announced...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU0588546209.SGD","BK1500","BK4139","LU1303224171.USD","LU1969619763.USD","LU1251922891.USD","LU0307460666.USD","BK1583","BK0239","BK1588","BK1161","688235","BK4526","LU2328871848.SGD","06160","ONC","LU1719994722.HKD","LU1770034418.SGD"],"gpt_icon":1},{"id":"1104425713","title":"HK Stock Movement | BEIGENE (06160) Opens Over 3% Higher as Phase 3 Clinical Study of Zanidatamab Combined with Tislelizumab and Chemotherapy Shows Positive Results","url":"https://stock-news.laohu8.com/highlight/detail?id=1104425713","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1104425713?lang=en_us&edition=fundamental","pubTime":"2025-11-18 09:28","pubTimestamp":1763429302,"startTime":"0","endTime":"0","summary":"BEIGENE (06160) opened over 3% higher, rising 3.53% to HK$223.2 by the time of reporting, with a trading volume of HK$11.96 million. On November 17, BEIGENE announced positive results from the Phase...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1969619763.USD","BK1161","LU1303224171.USD","BK4585","LU1770034418.SGD","BK4526","LU0588546209.SGD","LU1251922891.USD","BK1500","LU0307460666.USD","BK1583","BK4139","06160","BK0239","LU2328871848.SGD","ONC","BK1588","LU1719994722.HKD","688235"],"gpt_icon":1},{"id":"2584642320","title":"BeOne Medicines AG Reports Positive Phase 3 Results for ZIIHERA in HER2-Positive Gastroesophageal Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2584642320","media":"Reuters","labels":["productRelease","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584642320?lang=en_us&edition=fundamental","pubTime":"2025-11-17 19:00","pubTimestamp":1763377238,"startTime":"0","endTime":"0","summary":"BeOne Medicines AG has announced positive top-line results from the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA , a HER2-targeted bispecific antibody, in combination with chemotherapy, with or without the PD-1 inhibitor TEVIMBRA , as a first-line treatment for HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma . The trial demonstrated improvements in progression-free survival , overall survival , objective response rate , and duration of response  in the ZIIHERA plus TEVIMBRA and chemotherapy arm versus the control arm, in both PD-L1 positive and PD-L1 negative subgroups. The safety profile was consistent with previous data and no new safety signals were observed. The results will be submitted for presentation at a major medical meeting in the first quarter of 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"12b9cc00d05cc390c8f725385f7a4061","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251117:nNDL500nlP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688235","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2021-12-15","address":"c/oBeOneMedicinesIGmbH,Aeschengraben27,4051Basel,Switzerland","stockEarnings":[{"period":"1week","weight":-0.0108},{"period":"1month","weight":-0.0612},{"period":"3month","weight":-0.1242},{"period":"6month","weight":0.1093},{"period":"1year","weight":0.6506},{"period":"ytd","weight":0.6871}],"companyName":"百济神州有限公司","boardCode":"AI0027","perCapita":"3195股","boardName":"医药制造业","registeredCapital":"15万元","compareEarnings":[{"period":"1week","weight":0.0008},{"period":"1month","weight":-0.0161},{"period":"3month","weight":0.0147},{"period":"6month","weight":0.1537},{"period":"1year","weight":0.1461},{"period":"ytd","weight":0.1565}],"survey":"　　百济神州有限公司的主营业务是研究、开发、生产以及商业化创新型药物。公司的主要产品是百悦泽、百泽安、百汇泽、安加维、倍利妥、凯洛斯、萨温珂、凯泽百、普贝希（安维汀生物类似药）、百拓维（注射用戈舍瑞林微球）、泰菲乐（达拉非尼）、迈吉宁（曲美替尼）、维全特（帕唑帕尼）、飞尼妥（依维莫司）、赞可达（塞瑞替尼）。截至本报告期末，公司及其控股子公司拥有的发明专利包括美国发明专利64个、中国发明专利67个、日本发明专利30个、欧洲发明专利15个及其他国家或地区的发明专利135个。","serverTime":1766149937039,"listedPrice":192.6,"stockholders":"36008人(较上一季度增加55.74%)","compareStock":{"symbol":"000001.SH","name":"SSE Comp"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Beone Medicines Ltd.(688235),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Beone Medicines Ltd.(688235) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Beone Medicines Ltd.,688235,Beone Medicines Ltd.股票,Beone Medicines Ltd.股票老虎,Beone Medicines Ltd.股票老虎国际,Beone Medicines Ltd.行情,Beone Medicines Ltd.股票行情,Beone Medicines Ltd.股价,Beone Medicines Ltd.股市,Beone Medicines Ltd.股票价格,Beone Medicines Ltd.股票交易,Beone Medicines Ltd.股票购买,Beone Medicines Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Beone Medicines Ltd.(688235),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Beone Medicines Ltd.(688235) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}